LGP Denmark granted registration for its “Billinol LGP”

Company news

23 Nov 2021

Istockphoto 97418086 170667a

Little Green Pharma is pleased to announce it has been granted a product registration for its 16% THC “Billinol LGP” cannabis flower medicine by the Danish Medicines Agency.

The grant represents the culmination of a 2.5-year application process, with Billinol LGP being the first locally produced cannabis medicine in Denmark to receive product registration. Billinol LGP will be cultivated and produced at LGP’s Denmark Facility, with the LGP expecting to distribute its first products to patients before the end of the calendar year. Currently, Bedrocan is the only other medicinal cannabis manufacturer supplying cannabis flower into Denmark, with no other cannabis-based medicines available other than Sativex, Epidiolex and compounded formulations, making LGP only the second supplier to have a registered flower medicine in country.

The registration also gives the Group significant access to the 27 million people living in the Nordic region. Under mutual recognition agreements with Sweden, Norway and Finland, as well as through direct prescription by Danish prescribers, patients prescribed medicinal cannabis from these countries can access registered Danish cannabis medicines supplied by Danish distributors.

You might also be interested in

Team pic

Company news

Ring The Bell
Empowering a growing team to build a global brand

Nov 2020

Pharmacy

Insights

TGA announces final CBD down-scheduling
Registered CBD products to be dispensed over-the-counter without a prescription

Dec 2020

German Exports Approved for Little Green Pharma Flag

Company news

First Export Milestone Achieved

Little Green Pharma reaches a significant milestone becoming the first Australian medicinal cannabis producer to export samples of locally grown medicinal cannabis product to Germany.

Sep 2019

View all articles